Bristol-Myers Squibb is buying rival Celgene in a cash and stock deal valued at about $74bn (£58.8bn) or $90bn including debt. The tie-up, which is subject to various approvals and is expected to ...

Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be a close-run thing after the FDA extended the review of a cancer cell therapy close ...

Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company's development pipeline with cancer, immunology and cardiovascular treatments.

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

Celgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA backing its rare bone marrow cancer drug Inrebic. Inrebic (fedratinib) is one of a ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised ... the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, Celgene sold its mega-blockbuster ...